

Supplementary material


Dobrowolski P, Prejbisz A, Bożek G, et al. Use of individual antihypertensive drug classes and combination therapies during the COVID-19 pandemic in Poland: a cross-sectional, nationwide study in the years 2019–2021. *Pol Arch Intern Med.* 2024; 134: 16647. doi:10.20452/pamw.16647

Please note that the journal is not responsible for the scientific accuracy or functionality of any supplementary material submitted by the authors. Any queries (except missing content) should be directed to the corresponding author of the article.

Supplementary Table S1 Frequency of use of each group of antihypertensive drugs per total number of all filled antihypertensive drugs


Anihypertensive drug class	Percentage of all filled drugs in 2019	Percentage of all filled drugs in 2020	Percentage of all filled drugs in 2021	P value
Beta-blockers, %	27.3	27.4	27.5	<0.001
Angiotensin converting enzyme inhibitors, %	20.4	19.9	19.7	<0.001
Dihydropiridine calcium channel blockers, %	14.4	14.9	14.9	<0.001
Angiotensin receptor blockers, %	11.1	11.2	11.6	<0.001
Thiazide-like diuretics, %	9.3	9.1	9.0	<0.001
Thiazide diuretics, %	5.6	5.5	5.6	<0.001
Thiazide and thiazide-like diuretics, %	14.9	14.6	14.5	<0.001
Loop diuretics, %	5.5	5.4	5.5	<0.001
Mineralocorticoid receptor antagonists, %	3.4	3.4	3.4	<0.001
Alpha-adrenolitics, %	1.8	1.8	1.8	<0.001
Centrally acting drugs, %	0.6	0.6	0.6	<0.001
Non-dihydropiridine calcium channel blockers, %	0.6	0.5	0.5	<0.001
Other, %	<0.1	<0.1	<0.1	<0.001


Supplementary Figure S1 Frequency of use of antihypertensive drug classes in years 2019, 2020 and 2021 ($P < 0.001$ for each comparison between consecutive years)



Abbreviations: dhCCBs - dihydropyridine calcium channel blockers, ndhpCCBs - non-dihydropyridine calcium channel blockers, BBs - beta-blockers, MRAs - mineralocorticoid receptor antagonists, TLDs - thiazide-like diuretics, TDs - thiazide diuretics, LDs - loop diuretics, ABs – alpha blockers, ACEIs - angiotensin-converting enzyme inhibitors, ARBs - angiotensin II receptor blockers

Supplementary Figure S2. The most commonly used substances within each antihypertensive drugs group: **A** – angiotensin converting enzyme inhibitors; **B** – angiotensin receptor blockers; **C** – calcium channel blockers; **D** – β -blockers; **E** – thiazide and thiazide-like diuretics ($P < 0.001$ for each comparison between consecutive years)



B**C**